SG11201906579UA - Pyridine derivative as ask1 inhibitor and preparation method and use thereof - Google Patents

Pyridine derivative as ask1 inhibitor and preparation method and use thereof

Info

Publication number
SG11201906579UA
SG11201906579UA SG11201906579UA SG11201906579UA SG11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA SG 11201906579U A SG11201906579U A SG 11201906579UA
Authority
SG
Singapore
Prior art keywords
preparation
pyridine derivative
ask1 inhibitor
ask1
disclosed
Prior art date
Application number
SG11201906579UA
Other languages
English (en)
Inventor
Chengde Wu
Tao Yu
Ning Li
Shuhui Chen
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of SG11201906579UA publication Critical patent/SG11201906579UA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11201906579UA 2017-01-22 2018-01-22 Pyridine derivative as ask1 inhibitor and preparation method and use thereof SG11201906579UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201710054224 2017-01-22
PCT/CN2018/073640 WO2018133866A1 (zh) 2017-01-22 2018-01-22 作为ask1抑制剂的吡啶衍生物及其制备方法和应用

Publications (1)

Publication Number Publication Date
SG11201906579UA true SG11201906579UA (en) 2019-08-27

Family

ID=62907792

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906579UA SG11201906579UA (en) 2017-01-22 2018-01-22 Pyridine derivative as ask1 inhibitor and preparation method and use thereof

Country Status (18)

Country Link
US (1) US11040968B2 (ja)
EP (1) EP3572412B1 (ja)
JP (1) JP6650552B2 (ja)
KR (1) KR102089234B1 (ja)
CN (1) CN109071538B (ja)
AU (1) AU2018209574B2 (ja)
BR (1) BR112019014756B1 (ja)
CA (1) CA3050346C (ja)
DK (1) DK3572412T3 (ja)
EA (1) EA037005B1 (ja)
ES (1) ES2870524T3 (ja)
MX (1) MX2019008698A (ja)
MY (1) MY174821A (ja)
PH (1) PH12019501688A1 (ja)
PL (1) PL3572412T3 (ja)
SG (1) SG11201906579UA (ja)
WO (1) WO2018133866A1 (ja)
ZA (1) ZA201904737B (ja)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201833108A (zh) * 2017-03-03 2018-09-16 大陸商江蘇豪森藥業集團有限公司 醯胺類衍生物抑制劑及其製備方法和應用
JOP20190221A1 (ar) 2017-04-05 2019-09-23 Seal Rock Therapeutics Inc مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها
MX2019013275A (es) 2017-05-12 2020-07-27 Enanta Pharm Inc Inhibidores de la quinasa 1 reguladora de la señal de apoptosis y métodos de uso de estos.
WO2018218051A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218042A1 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
WO2018218044A2 (en) 2017-05-25 2018-11-29 Enanta Pharmaceuticals Inc Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN109400625B (zh) * 2017-08-17 2021-11-12 广东东阳光药业有限公司 稠合双环类化合物及其在药物中的应用
US10597382B2 (en) 2017-08-28 2020-03-24 Enanta Pharmaceuticals, Inc. Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
US11434249B1 (en) 2018-01-02 2022-09-06 Seal Rock Therapeutics, Inc. ASK1 inhibitor compounds and uses thereof
US10683289B2 (en) 2018-05-02 2020-06-16 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
IL278368B2 (en) 2018-05-02 2024-06-01 Enanta Pharm Inc Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods for its use
EP3825315B1 (en) * 2018-07-20 2022-08-31 Fujian Akeylink Biotechnology Co., Ltd. Crystal form as ask1 inhibitor, preparation method therefor, and application thereof
WO2020030107A1 (zh) * 2018-08-10 2020-02-13 江苏豪森药业集团有限公司 一种含有酰胺类衍生物的药物组合物及其制备方法和应用
WO2020034988A1 (zh) * 2018-08-14 2020-02-20 江苏豪森药业集团有限公司 凋亡信号调节激酶1抑制剂的盐及其晶型
US10968199B2 (en) 2018-08-22 2021-04-06 Enanta Pharmaceuticals, Inc. Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
CN110922407B (zh) * 2018-09-19 2021-11-12 广东东阳光药业有限公司 苯甲酰氨基吡啶衍生物的晶型及其用途
WO2020106707A1 (en) 2018-11-19 2020-05-28 Enanta Pharmaceuticals, Inc. Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof
JP7331116B2 (ja) * 2019-01-24 2023-08-22 チアンスー アオサイカン ファーマシューティカル カンパニー,リミティド TGF-βR1キナーゼ阻害剤としての5-(4-ピリジルオキシ)ピラゾール類化合物
US11466033B2 (en) 2019-03-25 2022-10-11 Enanta Pharmaceuticals, Inc. Substituted pyridines as apoptosis signal-regulating kinase 1 inhibitors
CN110577537B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577536B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577541B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577535B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577538B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577533B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577539B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577540B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN110577534B (zh) * 2019-07-16 2021-07-23 广州安岩仁医药科技有限公司 苯甲酰氨基吡啶衍生物的盐及其在药物中的应用
CN113831323A (zh) * 2020-06-24 2021-12-24 武汉人福创新药物研发中心有限公司 芳杂环酰胺类化合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI598347B (zh) * 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
UY34573A (es) * 2012-01-27 2013-06-28 Gilead Sciences Inc Inhibidor de la quinasa que regula la señal de la apoptosis
CN103570625A (zh) * 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2015095059A1 (en) * 2013-12-20 2015-06-25 Gilead Sciences, Inc. Apoptosis signal-regulating kinase inhibitors

Also Published As

Publication number Publication date
CN109071538A (zh) 2018-12-21
CN109071538B (zh) 2020-03-17
BR112019014756A2 (pt) 2020-03-03
JP6650552B2 (ja) 2020-02-19
JP2020504166A (ja) 2020-02-06
EP3572412A1 (en) 2019-11-27
ZA201904737B (en) 2020-05-27
US11040968B2 (en) 2021-06-22
ES2870524T3 (es) 2021-10-27
EP3572412A4 (en) 2019-11-27
EP3572412B1 (en) 2021-03-03
PH12019501688A1 (en) 2020-03-09
MX2019008698A (es) 2019-09-18
WO2018133866A1 (zh) 2018-07-26
EA201991693A1 (ru) 2019-12-30
DK3572412T3 (da) 2021-05-25
CA3050346A1 (en) 2018-07-26
US20200031823A1 (en) 2020-01-30
KR20190110103A (ko) 2019-09-27
AU2018209574B2 (en) 2021-04-08
PL3572412T3 (pl) 2021-09-27
BR112019014756B1 (pt) 2021-08-10
MY174821A (en) 2020-05-18
CA3050346C (en) 2020-07-14
AU2018209574A1 (en) 2019-09-05
KR102089234B1 (ko) 2020-05-15
EA037005B1 (ru) 2021-01-26

Similar Documents

Publication Publication Date Title
PH12019501688A1 (en) Pyridine derivative as ask1 inhibitor and preparation method and use thereof
PH12018550120A1 (en) Steroid derivative fxr agonist
MX2023001876A (es) Derivados de rapamicina.
MX2018001491A (es) Metodos para la preparacion de acidos biliares y derivados de los mismos.
PH12018500360A1 (en) Heteroaryl derivatives as parp inhibitors
MX2017013797A (es) Inhibidor de janus quinasa.
SA519402288B1 (ar) مركب بيريميدين واستخداماته الصيدلانية
PH12019500480A1 (en) Pyridine compound
MX2023004309A (es) Inhibidores de quinasa alk2 que contienen imidazol.
MX2024009886A (es) Derivados de quinolina como inhibidores de integrina alfa4beta7.
MX2021006544A (es) Inhibidores de cinasa dependiente de ciclina 9 (cdk9) y polimorfos de los mismos para uso como agentes para el tratamiento de cancer.
NZ745349A (en) Urea compound, preparation method therefor and medical use thereof
PH12019501955A1 (en) Tri-cycle compound and applications thereof
SA520411635B1 (ar) A2a مشتق حلقي مدمج كمثبط مستقبل
MX2021007247A (es) Derivados de rapamicina.
MX2017000208A (es) Derivados de quinolizinona como inhibidores de pi3k.
PH12016502246A1 (en) Carboxamide derivatives
PH12019550154A1 (en) Azetidine derivative
PH12020550649A1 (en) Anti-hbv tetrahydroisoxazolo[4,3-c]pyridine compounds
PH12021550572A1 (en) Novel thiazole derivatives and pharmaceutically acceptable salts thereof
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
ZA201904033B (en) Pharmaceutical compounds